Champions Oncology (NASDAQ: CSBR) is drawing attention from retail investors, with its recent price percent change of 5.86% signaling potential momentum in the biotechnology sector. Despite a maximum drawdown of 22.49, the stock's current price of
4.88 suggests that investors are intrigued by its potential upside of 6.56, indicating a growing interest in its future prospects.
Key Points
Champions Oncology currently holds a "Strong Buy" rating from one analyst. To enhance this expert consensus, we offer trading advice based on our advanced recommendation engine. This tool employs a sophisticated algorithm that evaluates the company's growth potential by examining all available technical and fundamental data.
The successful prediction of Champions Oncology
stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published
stock prices of traded companies, such as Champions Oncology, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at
the intrinsic value of Champions Oncology based on Champions Oncology hews, social hype, general headline patterns, and widely used
predictive technical indicators. We also calculate exposure to Champions Oncology's
market risk, different
technical and
fundamental indicators, relevant financial multiples and ratios, and then
comparing them to Champions Oncology's related companies.
Use Technical Analysis to project Champions expected Price
Champions Oncology technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Champions Oncology technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Champions Oncology trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions.
More Info...Champions Oncology Gross Profit
Champions Oncology Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Champions Oncology previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Champions Oncology Gross Profit growth over the last 10 years. Please check Champions Oncology's
gross profit and other
fundamental indicators for more details.
Breaking down Champions Oncology Further
The latest price spike of Champions Oncology could raise concerns from retail investors as the firm is trading at a share price of
4.88 on
18,443 in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in
January. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.51. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Champions Oncology partners.
| 2021 | 2022 | 2023 | 2024 (projected) |
Short Long Term Debt Total | 9.5M | 8.6M | 7.4M | 7.8M | Total Assets | 35.4M | 34.3M | 26.1M | 27.4M |
Current Deferred Revenue Breakdown
Champions Oncology Current Deferred Revenue yearly trend continues to be relatively stable with very little volatility. Current Deferred Revenue is likely to grow to about 12.7
M this year. Current Deferred Revenue usually refers to revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends. At this time, Champions Oncology's Current Deferred Revenue is relatively stable compared to the past year.
| 2017 | 4.7 Million |
| 2018 | 4.02 Million |
| 2019 | 5.82 Million |
| 2020 | 6.26 Million |
| 2021 | 11.07 Million |
| 2022 | 12.78 Million |
| 2023 | 12.09 Million |
| 2024 | 12.7 Million |
They say, "The trend is your friend," and Champions Oncology (NASDAQ: CSBR) might just be riding a wave of retail investor interest. Despite a challenging financial landscape, with a debt-to-equity ratio of 1.03% and a return on equity at a loss of 4.32%, the company is garnering attention. With 49% of its shares owned by institutions, there's a notable foundation of institutional support, yet the stock's high price-to-earnings ratio of 220.00X suggests a premium valuation that might be driven by future growth expectations. Retail investors are likely intrigued by the potential upside, but the probability of bankruptcy at 41.59% is a reminder of the inherent risks in the biotechnology sector. As retail investors weigh these factors, the allure of Champions Oncology lies in its potential to capitalize on innovation within life sciences tools and services.
Our take on today Champions Oncology spike
Champions Oncology saw a significant jump today, but with the potential upside now capped at 6.56, it seems the stock's recent momentum might be waning. This could mean reduced volatility as the market settles around this new price. Investors should monitor the stock's behavior in the coming days, as this change might indicate a consolidation phase or a possible pullback. While the excitement of the surge is understandable, it's important to stay cautious and consider the broader market context before making any trading moves. Champions Oncology exhibits above-average downside volatility for the chosen time frame.
Understanding market volatility trends can help investors time their trades. Using volatility indicators effectively allows traders to assess the stock's risk against market fluctuations in both rising and falling markets.Despite today's modest market decline, Champions Oncology's robust performance suggests a compelling opportunity for investors. With an Analyst Overall Consensus rating of "Strong Buy" and a potential upside price reaching up to 8.96, the stock demonstrates significant promise. The highest estimated target price by analysts stands at 9.71, indicating confidence in its future growth. As the company continues to innovate and expand its oncology solutions, its valuation market value of 4.88 seems to provide a solid foundation for potential investors. While no investment is without risk, Champions Oncology's current trajectory and expert endorsements suggest it could be a rewarding addition to a diversified portfolio..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Champions Oncology. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
